BPC 157 therapy to detriment sphincters failure-esophagitis-pancreatitis in rat and acute pancreatitis patients low sphincters pressure.
Possibly, acute esophagitis and pancreatitis cause each other, and we focused on sphincteric failure as the common causative key able to induce either esophagitis and acute pancreatitis or both of them, and thereby investigate the presence of a common therapy nominator. This may be an anti-ulcer pentadecapeptide BPC 157 (tested for inflammatory bowel disease, wound treatment) affecting esophagitis, lower esophageal and pyloric sphincters failure and acute pancreatitis (10 μg/kg, 10 ng/kg intraperitoneally or in drinking water). The esophagitis-sphincter failure procedure (i.e., insertion of the tubes into the sphincters, lower esophageal and pyloric) and acute pancreatitis procedure (i.e., bile duct ligation) were combined in rats. Esophageal manometry was done in acute pancreatitis patients. In rats acute pancreatitis procedure produced also esophagitis and both sphincter failure, decreased pressure 24 h post-surgery. Furthermore, bile duct ligation alone immediately declines the pressure in both sphincters. Vice versa, the esophagitis-sphincter failure procedure alone produced acute pancreatitis. What's more, these lesions (esophagitis, sphincter failure, acute pancreatitis when combined) aggravate each other (tubes into sphincters and ligated bile duct). Counteraction occurred by BPC 157 therapies. In acute pancreatitis patients lower pressure at rest was in both esophageal sphincters in acute pancreatitis patients. We conclude that BPC 157 could cure esophagitis/sphincter/acute pancreatitis healing failure.
Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia.
I
I
Petrovic
I
I
Dobric
D
D
Drmic
M
M
Sever
R
R
Klicek
B
B
Radic
L
L
Brcic
D
D
Kolenc
M
M
Zlatar
K
K
Kunjko
D
D
Jurcic
M
M
Martinac
Z
Z
Rasic
A
A
Boban Blagaic
Z
Z
Romic
S
S
Seiwerth
P
P
Sikiric
D000208:Acute Disease; D000284:Administration, Oral; D000818:Animals; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D016145:Endoscopy, Digestive System; D049630:Esophageal Sphincter, Lower / Q000187:drug effects* / Q000503:physiopathology*; D004941:Esophagitis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D008297:Male; D008365:Manometry; D008875:Middle Aged; D010195:Pancreatitis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D010446:Peptide Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D011312:Pressure; D011506:Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D016896:Treatment Outcome
D000897:Anti-Ulcer Agents; D010446:Peptide Fragments; D011506:Proteins; C083833:BPC 157